ACADIA Pharmaceuticals Inc. — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014. Unaudited interim financial statements; amounts below are in U.S. dollars unless stated otherwise.
Business context
ACADIA is a clinical-stage biopharmaceutical company with no product sales to date. Its lead candidate, pimavanserin, is being developed for Parkinson’s disease psychosis (PDP); the company was completing NDA-enabling clinical and manufacturing work and planned to submit an NDA to the FDA near the end of 2014. Pimavanserin was also in Phase II development for Alzheimer’s disease psychosis, with further schizophrenia studies planned. Chronic-pain and glaucoma programs were being developed with Allergan.
Financial results and liquidity
| Metric | Q2 2014 | Q2 2013 | First half 2014 | First half 2013 |
|---|---|---|---|---|
| Revenue | $28,000 | $451,000 | $58,000 | $868,000 |
| Research and development expense | $13.8m | $7.1m | $25.5m | $11.5m |
| General and administrative expense | $8.0m | $2.5m | $14.3m | $4.6m |
| Operating loss | $21.7m | $9.2m | $39.7m | $15.3m |
| Net loss | $21.5m | $9.1m | $39.3m | $15.2m |
| Net loss per share, basic and diluted | $0.22 | $0.11 | $0.41 | $0.19 |
Revenue was collaboration and grant-related, not product revenue. No meaningful operating margin is presented; the company reported operating losses. The filing does not provide a clear gross-margin figure.
- Cash and investments: $354.5m at June 30, 2014, versus $185.8m at December 31, 2013. This comprised $13.7m cash and cash equivalents and $340.8m available-for-sale investments.
- Cash flow, first half: $31.1m used in operations, $166.6m used in investing (primarily net investment-security purchases), and $199.8m provided by financing. Cash increased $2.0m to $13.7m.
- Capital raise: March 2014 public offering generated $196.8m net proceeds; financing cash flow also included other issuance proceeds. Shares outstanding were 99.3m at June 30 and 99,436,825 as of July 31, 2014.
- Liquidity and debt: Current assets were $358.9m and current liabilities $9.3m; total liabilities were $9.4m. The balance sheet reports no debt line item. Management expected available cash, cash equivalents and investments to fund planned operations at least into 2017.
Material changes versus prior comparable periods
- First-half revenue fell to $58,000 from $868,000, principally because the 2003 Allergan research collaboration ended in March 2013 and grant activity declined. The two ongoing Allergan collaborations generated only $22,000 in first-half 2014 revenue.
- First-half R&D expense more than doubled, mainly due to higher external costs for pimavanserin’s Phase III and NDA-enabling work and expansion of the R&D organization.
- First-half G&A expense rose substantially as ACADIA expanded administrative and pre-commercial operations. Stock-based compensation increased to $7.5m for the half from $1.6m; the 2014 expense included $1.7m related to modifying the former CFO’s options in connection with his retirement.
- Equity increased significantly following the March offering; common shares outstanding rose from 91.1m at year-end 2013 to 99.3m at June 30, 2014.
Outlook, risks and contingencies
- Management expected losses and substantial R&D and G&A spending to continue, with expenses likely to increase as pimavanserin development and commercialization preparations advance. Profitability timing was uncertain.
- The NDA plan remained subject to completion of supporting studies and manufacturing work and FDA review. FDA agreement that available trial data could support filing did not assure acceptance or approval; approval scope, labeling, or post-approval requirements could constrain commercialization.
- ACADIA had no approved products and was solely responsible for pimavanserin’s development and potential U.S. commercialization. It had limited commercialization experience and would need to build sales and marketing capabilities or find partners.
- Funding beyond the stated runway could be needed. If additional capital or collaboration funding is unavailable on acceptable terms, the company may need to delay, reduce, or discontinue programs or license rights on less favorable terms.
- Allergan’s ongoing programs faced partner-related uncertainty: Allergan could terminate the agreements, had announced a search for a chronic-pain partner, and had announced restructuring and headcount reductions. Future milestone payments and royalties depend on successful development and commercialization.
- Contractual commitments included up to approximately $22.7m of future external-provider services, generally stoppable on short notice without liability for the full amount; $2.1m of operating lease obligations; and potential Ipsen milestone payments of up to $10.5m, subject to specified events and offsets. The filing identifies commitments and contingencies but reports no specific pending litigation contingency.
- Investment holdings were high-quality, marketable securities; management stated a 10% interest-rate change would not materially affect portfolio fair value. The filing also identifies clinical, regulatory, manufacturing, reimbursement, intellectual-property, collaboration, financing and commercialization risks.
Most important facts for investors to verify
- Whether the planned end-2014 pimavanserin PDP NDA was completed and how the FDA handled it.
- Whether the reported cash-and-investment runway into 2017 remained adequate as development and launch-preparation spending increased.
- Future cash burn, stock-based compensation, dilution and any additional financing needs.
- Progress and funding commitments for the Allergan chronic-pain and glaucoma collaborations, including effects of Allergan’s restructuring or any partnership changes.
- Whether the $22.7m external-service commitments, Ipsen milestone exposure and other contingencies changed materially.